Fennec Pharmaceuticals (FENC) Cash & Equivalents (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Cash & Equivalents data on file, last reported at $36.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 38.12% year-over-year to $36.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.8 million (up 38.12% YoY) and the FY2025 annual result came in at $36.8 million, up 38.12% from the prior year.
• Cash & Equivalents grew to $36.8 million in Q4 2025, from $21.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $51.2 million in Q1 2024 to a low of $12.4 million in Q3 2023.
• A 5-year average of $25.1 million and a median of $23.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 58.33% — and 2024, when it soared 285.74%.
• Tracing FENC's Cash & Equivalents over 5 years: stood at $21.1 million in 2021, then advanced by 12.67% to $23.8 million in 2022, then slumped by 44.19% to $13.3 million in 2023, then soared by 100.72% to $26.6 million in 2024, then jumped by 38.12% to $36.8 million in 2025.
• The last three Cash & Equivalents figures came in at $36.8 million (Q4 2025), $21.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.